Home » Stocks » ADAG

Adagene, Inc. (ADAG)

Stock Price: $23.11 USD 0.12 (0.52%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $23.29 +0.18 (0.78%) Mar 5, 6:56 PM
Market Cap 974.78M
Revenue (ttm) 790,000
Net Income (ttm) -34,243
Shares Out 42.33M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $23.11
Previous Close $22.99
Change ($) 0.12
Change (%) 0.52%
Day's Open 22.85
Day's Range 22.00 - 23.18
Day's Volume 70,573
52-Week Range 20.21 - 31.83


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming...

GlobeNewsWire - 3 weeks ago

SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to tran...

Business Wire - 1 month ago

Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s SAFEbody™ technology platform...

NASDAQ - 1 month ago

Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering.

SEC - 1 month ago

Adagene, Inc. has filed to go public with an IPO on the NASDAQ.

Endpoints News - 1 month ago

Dragonfly’s partnership with AbbVie is beginning to bear fruit. AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment,...

Contract Pharma - 1 month ago

Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.

About ADAG

Adagene, a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for th... [Read more...]

IPO Date
Feb 9, 2021
Peter (Peizhi) Luo, Ph.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, Adagene's revenue was $480,000, a decrease of -68.24% compared to the previous year's $1.51 million. Losses were -$16.43 million, 7.64% more than in 2018.

Financial Statements